← All trials
NCT00219882
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2005
- Primary completion
- —
- Completion date
- Jan 1, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- 11
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of WashingtonLead sponsor
- Seer PharmaceuticalsCollaborator
- University of WashingtonOverall official - principal investigator
- CF Therapeutics Development Network Coordinating CenterCollaborator
- Cystic Fibrosis Foundation TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.